Business
University of British Columbia Launched as Newest Clinical Study Site for Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
TORONTO, ON / ACCESSWIRE / December 7, 2020 / Theralase ® Technologies Inc. (" Thera...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"University of British Columbia Launched as Newest Clinical Study Site for Phase II Non-Muscle Invasive Bladder Cancer Clinical StudyTORONTO, ON / ACCESSWIRE / December 7, 2020 / Theralase® Technologies Inc. (\"Theralase\" or the \"Company\") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (\"PDC\") and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today that the University of British Columbia (\"UBC\") Review Ethics Board (\"REB\") has approved the commencement of a Pivotal Phase II Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Clinical Study to enroll and treat patients who present with Carcinoma In-Situ (\"CIS\") and who are considered Bacillus Calmette Guerin(\"BCG\")-Unresponsive or are intolerant to BCG Therapy (\"Study II\").The University of British Columbia is a global center for teaching, learning and research, consistently ranked among the top 20 public universities in the world and recently recognized as North America's most international university.To date 14 patients have been treated in Study II. With the addition of UBC, the Company now has 5 sites open for patient enrollment and treatment in Canada. The Company is in advanced discussions to launch a number of U.S. based clinical study sites in 4Q2020, subject to the United States economy recovering from the COVID-19 pandemic. The U.S. based Trial Management Organization plans to launch 4 to 5 clinical study sites in 4Q2020 and commence Study II patient enrollment and treatment as early as 1Q2021.Dr. Peter Black, MD, FRCSC, a Urologic Oncologist at Vancouver General Hospital, a Research Scientist at the Vancouver Prostate Centre, and a Professor in the Department of Urologic Sciences at the University of British Columbia stated \"I think this is a great opportunity for patients to gain access to a promising new technology and treatment that is easy to deliver and very patient-friendly. We are delighted to be able to offer it to patients in British Columbia.\"Shawn Shirazi PhD, Chief Executive Officer, Theralase®, stated, \"We are extremely pleased that the UBC, REB provided approval to proceed with Study II. We are excited that our recent FDA Fast Track Designation status for Stud...